Actively Recruiting
Evaluation of Safety and Efficacy of Multiple Pulsed Focused Ultrasound Using NaviFUS System for Drug Resistant Temporal Lobe Epilepsy
Led by Genovate-NaviFUS (Australia) Pty Ltd. · Updated on 2026-09-10
18
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and efficacy of the NaviFUS System, a neuronavigation-guided focused ultrasound device, for treating patients with drug-resistant temporal lobe epilepsy TLE. This study addresses the need for noninvasive alternatives to surgery and invasive neuromodulation for people whose epilepsy does not respond to medication and who are not suitable for resective surgery. Participants will receive focused ultrasound treatment targeting one or both hippocampi using the NaviFUS System. The study includes two groups Cohort 1 will have two ultrasound treatments per week for two weeks, and Cohort 2 will have the same treatment schedule but extended to three weeks. Both cohorts undergo safety follow-up visits after treatment to monitor effects. Participants will be involved in a 60-day baseline screening period before treatment. During the study, researchers will assess seizure frequency, neurological and physical exams, MRI and ECG scans, and cognitive function tests using several neuropsychological assessments. Safety monitoring continues for up to three months after the last treatment, including tracking adverse events and changes in cognitive function, with a total follow-up lasting about 81 days after treatment.
CONDITIONS
Brief Title
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
Research Team
R
Reannan Duong, Ms.
J
Jack Germaine, Mr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here